Abstract
Acquired resistance frequently develops in humans after the initial use of cis-diamminedichloroplatinum(II) (CP). Furthermore, both clinical and laboratory results suggest tumor cells with resistance to CP are often cross resistant to other structurally and mechanistically distinct agents. For example, the human squamous cell carcinoma SCC25/CP, which has 12-fold acquired resistance to CP, is also approximately 7-fold resistant to methotrexate, 5-fold resistant to melphalan and 3-fold resistant to cyclophosphamide (Kelley et al., 1988). Studies with other cells suggest CP resistance can be associated with cross resistance to x-radiation in human tumor cell lines (Schwartz et al., 1988). Thus, brief or repeated exposure to CP can lead to cross resistance to other cancer therapeutics but the mechanism for the drug cross-resistance is not known. Moreover, the generation of anticancer drug cross-resistance is not unique to CP and can be seen with other agents. Because many anticancer agents are genotoxic, altered gene expression might occur after drug treatment. Indeed, increased gene expression is frequently seen in cells with acquired resistance to anticancer drugs. The focus of the work described in this manuscript has been to examine the mechanistic basis for alter gene expression in a human cell line with acquired resistance to CP.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bahnson, R.R., Becich, M., Ernstoff, M.S., Sandlow, J., Cohen, M., and Williams, R.D., 1974, Absence of immunohistochemical metallothionein staining in bladder tumors specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy, J. Urol. 152:2272–2275.
Basu, A. and Lazo, J.S., 1991, Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloroplatinum (II) resistance by v-mos, Cancer Res. 51:893–896.
Compere S.J. and Palmiter R.D., 1981, DNA methylation controls the inducibility of the mouse metallothionein-I gene in lymphoid cells, Cell 25:233–240.
Cornwell, M.M. and Smith, D.E., 1993, SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity, J. Biol. Chem. 268:19505–19511.
Haslinger, A. and Karin, M., 1985, Upstream promoter element of the human metallothionein-IIA gene can act like an enhancer element, Proc. Natl. Acad. Sci., USA 82:8572–8576.
Heguy, A., West, A., Richards, R.I., and Karin, M., 1986, Structure and tissue-specific expression of the human metallothionein Iβ gene, Mol. Cell Biol. 6:288149–2157.
Kelley, S.L., Basu, A., Teicher, B.A., Hacker, M.P., Hamer, D.H. and Lazo, J.S., 1988, Overexpression of metallothionein confers resistance to anticancer drugs, Science 241:1813–1815.
Kondo, Y., Kuo, S.-M. and Lazo, J.S., 1994, Interleukin 1β mediated metallothionein induction and cytoprotection against cadmium and cis-diamminedichloroplatinum, J. Pharmacol. Exp. Therap. 270:1313–1318.
Kondo, Y., Woo, E.S., Michalska, A.E., Choo, K.H.A and Lazo, J.S., In Press, Metallothionein null cells have increased sensitivity to anticancer drugs, Cancer Res.
Lazo, J.S., Kondo, Y. Dellapiazza, D., Michalska, A.E., Choo, K.H.A., and Pitt, B.R., 1995, Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in metallothionein I and II genes, J. Biol. Chem. 270:5506–5510.
Lazo, J.S. and Pitt, B.R., In Press, Metallothionein and Cell Death, Ann. Rev. Pharmacol and Toxicol.
Lee, W. Mitchell, P. and Tjian, R, 1987, Activation of transcription by two factors that bind promoter and enhancer sequence of the human metallothionein gene and SV40, Nature 325:368–372.
Lee, K.B., Parker, R.J., Bohr, V., Cornelison, T. and Reed, E., 1993, Cisplatin sensitivity/resistance to UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3, Carcinogenesis 14:2177–2180.
Lemkuil, D.C., Nettesheim, D., Shaw, C.F., III and Petering, D.H., 1994, Reaction of Cd7 metallothionein with cis-diamminedichloroplatinum(II), J. Biol. Chem. 269:24792–24797.
Lieberman, M.W., Beacher, L.R., and Palmiter, R.D., 1993, Ultraviolet radiation-induced metallothionein-I gene activation is associated with extensive DNA demethylation, Cell 35:207–214.
Ma, L., Weeda, G., Jochemsen, A.G., Bootsma, D., Hoeijmakers, J.H. and Eb, A.J. v.d., 1991, Molecular and functional analysis of the XPBC/ERCC promoter: transcription activity is dependent on the integrity of an Sp-1 binding site, Nucleic Acids Res. 20:217–2241.
Michalska, A. E. and Choo, K.H.A., 1993, Targeting and germ-line transmission of a null mutation at the metaUothionein I and II loci in mice, Proc. Natl. Acad. Sci. USA 90:8088–8092.
Murphy D.A., McGrown, A.T., Crowther, D., Manered, A. and Fox, B.W., 1991, MetaUothionein levels in ovarian tumors before and after chemotherapy. Br. J. Cancer 63:711–714.
Scholer, H., Haslinger, A., Heguy, A., Holtgreve, H., and Karin, M., 1986, In vivo competition between metaUothionein regulatory elements and the SV40 enhancer. Science 232:76–80.
Schwartz, J.L., Rotmensch, J., Beckett, M.A., Jaffe, D.R., ToohiU, M., Giovanazzi, S.M., McIntosh, J. and Weichselbaum, R. R, 1988, X-ray and cis-diamminedichloroplatinum(II) is cross-resistant in human tumor ceU lines, Cancer Res. 48:5133–5135.
Yang, Y.-Y., Woo, E.S., Reese, C.E., Bahnson, R.R., Saijo, N. and Lazo, J.S., 1994, Human metaUothionein isoform gene expression in cisplatin-sensitive and resistant cells, Mol. Pharm. 45:453–460.
Yang, Y.-Y., Ph.D. Dissertation, 1994, Regulation of human metaUothionein gene expression in cisplatin sensitive and resistant cells, University Microfilms, Inc.
Yokoyama, Y., Kawamoto, T., Mitsuuchi, Y., Kurosaki, T., Toda, K., Ushiro, H., Terashima, M., Summoto, H., Kuribayashi, I., Yamamoto, Y., Maeda, T., Ikeda, H., Sagara, Y. and Shizuta, Y., 1991, Human poly(ADP-ribose) polymerase gene: cloning of the promoter region, Eur. J. Biochem. 194:521–526.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lazo, J.S., Yang, YY. (1996). Transcription Factor Differences in Cisplatin Resistant Cells. In: Pinedo, H.M., Schornagel, J.H. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0218-4_32
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0218-4_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0220-7
Online ISBN: 978-1-4899-0218-4
eBook Packages: Springer Book Archive